A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. METHODS: In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. RESULTS: A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was -348 μg per liter (95% confidence interval, -517 to -179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. CONCLUSIONS: The percentage of patients with transfusion-dependent β-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
Citations
Cites
Global epidemiology of haemoglobin disorders and derived service indicators
Modell, B. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.06.036673 · Cited by 1,924
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Self-citationWood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., & Coates, T. D. (2005) · Blood · doi:10.1182/blood-2004-10-3982 · Cited by 1,045
Self-citationNoninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., & Lindeman, R. (2005) · Blood · doi:10.1182/blood-2004-01-0177 · Cited by 909
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 903
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationSurvival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
Modell, B., Khan, M., & Darlison, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 583
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392
Self-citation
Cited by
Items 201–300 of 337
Akpan, I. J., Bogyo, K., Leeman‐Neill, R. J., Wattacheril, J. J., & Francis, R. O. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1389820 · Cited by 3
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemia
Musallam, K. M. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00003-1 · Cited by 3
Alabi, F. A., Okpalanwaka, I. F., Oyegbesan, A., Okoyeocha, E. O. M., Oladejo, M., & Imodoye, S. O. (2025) · MedComm – Oncology · doi:10.1002/mog2.70027 · Cited by 8
kou, Y.-Y., Liu, J., Chang, Y., Liu, L., Sun, F., Li, Y., Leng, J.-R., Lin, H., & Yang, F. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00968-0 · Cited by 3
Kosugi, H., Fujisaki, T., Iwasaki, H., Shinagawa, A., Iida, H., Jo, T., Kubonishi, S., Morita, Y., Nakashima, Y., Onodera, K., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03872-3 · Cited by 4
Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
Jackson, N., Khairullah, S., & Bee, P. C. (2020) · eJHaem · doi:10.1002/jha2.54 · Cited by 3
“showed that luspatercept reduces transfusion requirements in some patients with transfusion-dependent β-thalassemia [3].”
BackgroundSelf-citationKhandros, E., & Kwiatkowski, J. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821671-2.00013-1 · Cited by 4
Diagnostic Modalities in Detecting Cardiovascular Complications of Thalassemia
Fianza, P. I., Pramono, A. A., Ghozali, M., Sihite, T. A., Setiabudi, D., Syamsunarno, M. R. A. A., Fucharoen, S., & Panigoro, R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308267 · Cited by 3
“A ten-year-long cohort of TDT patients demonstrated that a high-risk cardiac T2* value is associated with decreased survival rate in the long term [46].”
BackgroundSuwito, B. E., Adji, A. S., Widjaja, J. S., Angel, S. C. S., Hajiri, A. Z. Z. A., Salamy, N. F. W., & Choirotussanijjah, C. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.11435 · Cited by 4
Real-life experience with luspatercept in transfusion-dependent β-thalassemia
Roccotelli, D., Grande, D., Cicco, G., Palma, A. M., Longo, M. C., Albano, F., Vitucci, A., & Musto, P. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05381-5 · Cited by 3
Cellular and immunotherapies for myelodysplastic syndromes
Stubbins, R. J., Cherniawsky, H. M., & Karsan, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.006 · Cited by 4
Longo, F., Tesio, N., Piolatto, A., Ferrero, G. B., & Piga, A. G. (2021) · Future Rare Diseases · doi:10.2217/frd-2021-0012 · Cited by 3
Self-citationMulas, O., Pili, I., Sanna, M., & Nasa, G. L. (2021) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/17450179-v17-e211208-2021-ht2-1910-4 · Cited by 3
Glenthøj, A. B., Rasmussen, A. Ø., Bendtsen, S. K., Hasle, H., Hoffmann, M. H., Rieneck, K., Dziegiel, M. H., Sjø, L. D., Frederiksen, H., Hansen, D. L., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03298-4 · Cited by 2
Current therapeutic landscape of β-thalassemia: focus on gene therapy
Cheng, A. N., & Kwiatkowski, J. L. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261433028 · Cited by 4
“6,7 Mitapivat and etavopivat, two pyruvate kinase activators, are currently under study for their potential to improve erythropoiesis and red cell lifespan and mitigate anemia in TDT. 8,9 However, none of these agents provides a definitive cure.”
Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP–SMAD Signaling to Therapeutic Modulation
Duminuco, A., Costa, A. N., Pilo, F., Scarso, S., Giallongo, C., Giallongo, S., Santisi, A., Sbriglione, A., Santocono, L., Caocci, G., et al. (2026) · Biomolecules · doi:10.3390/biom16070947 · Cited by 3
“Mechanistically, this attenuates erythroblast apoptosis and ERFE secretion, thereby indirectly normalizing the hepcidin–ferroportin axis [75].”
The expanding therapeutic landscape of β-thalassaemia
Musallam, K. M., Sheth, S., Locatelli, F., Shah, F., Rivella, S., Kuo, K. H. M., Forni, G. L., Kattamis, A., Aydınok, Y., Glenthøj, A. B., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00173-0 · Cited by 3
Self-citationYamaguchi, A., Hirano, I., Narusawa, S., Shimizu, K., Ariyama, H., Yamawaki, K., Nagao, K., Yamamoto, M. P., & Shimizu, R. (2021) · Genes to Cells · doi:10.1111/gtc.12887 · Cited by 2
Boccadifuoco, U., Cheminet, G., Morino, B., & Arlet, J. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.12.006 · Cited by 2
Luzzatto, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00143-2 · Cited by 3
Effect of Educational Intervention On Nursing Care in Patients Diagnosed with Thalassemia Major
Tabussam, S., Afzal, M., Sarwar, H., & Khan, S. N. (2022) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v3i06.357 · Cited by 2
Innovative and Needs-led research on β-thalassemia treatment methods
Dan, M.-O., Gutu, B.-I., Severin, E. M., & Tanase, V.-G. (2023) · Frontiers in Hematology · doi:10.3389/frhem.2022.1085952 · Cited by 2
Diamantidis, M. D., Pitsava, S., Zayed, O., Argyrakouli, I., Karapiperis, K., Chatzoulis, C., Alexiou, E., Manafas, A., Tsangalas, E., & Karakousis, K. (2023) · Hematology Reports · doi:10.3390/hematolrep15030050 · Cited by 2
“On the other hand, luspatercept is an agent used in the recent years for the treatment of anemia of transfusion-dependent beta thalassemia (TDT) (BELIEVE study) [17] and non-transfusion dependent beta thalassemia (NTDT) (BEYOND study) [18].”
BackgroundLi, Y., Ye, L., Zhou, K., Fan, H., Li, J., Xiong, Y., Yang, Y., Peng, G., Yang, W., Zhao, X., et al. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i19.3978 · Cited by 2
Torti, L., Ardu, N. R., MAFFEI, L. E., de Fabritiis, P., & Sorrentino, F. (2024) · eJHaem · doi:10.1002/jha2.1032 · Cited by 2
Gammon, R. R., Rahimi‐Levene, N., Bandeira, F. M. G. D. C., & Al‐Riyami, A. Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-67332-0_9 · Cited by 2
Liu, J., Bai, Y., Leng, Y.-E., Chang, E., Wei, Y., & Wei, W. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2464071 · Cited by 3
“The majority of luspatercept’s side effects in clinical trials were well tolerated, with thromboembolic events, hypertension, and bone pain being of special concern [13,14].”
Detection of activin receptor type IIA and IIB‐Fc fusion proteins by automated capillary immunoassay
Desharnais, P., & Naud, J. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3378 · Cited by 2
Zhu, D., Liang, G., Zhang, Y., Wei, X., Wu, X., & Shang, X. (2022) · British Journal of Haematology · doi:10.1111/bjh.18512 · Cited by 2
Girelli, D., & Busti, F. (2020) · Haematologica · doi:10.3324/haematol.2020.253393 · Cited by 3
Can any new thalassemia therapy achieve a better than 97.4% cure rate?
Angelucci, E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25952 · Cited by 2
“therapy has shown remarkable improvements with the availability of the new erythroid stimulating agent luspatercept.(14) For any patients having an available HLA identical donor inside the family or in an”
BackgroundLuspatercept in patients with non-transfusion dependent β-thalassaemia
Platzbecker, U., & Morison, J. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00256-3 · Cited by 2
Borate, U. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm114.pub2 · Cited by 2
Deironing the spleen with luspatercept
Girelli, D., & Marchi, G. (2023) · Blood · doi:10.1182/blood.2023022548 · Cited by 2
Pitsillidou, O., Petrou, P., & Postma, M. J. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00482-x · Cited by 2
Sobrecarga hepática de hierro: implicaciones postransfusionales
Villalobos-Orozco, M. W., Vizcaíno-Carruyo, J. C., & Vizcaíno, G. (2025) · Hepatología · doi:10.59093/27112330.132 · Cited by 1
Novel Therapeutic Advances in β-Thalassemia
Srichairatanakool, S., & Tantiworawit, A. (2025) · Journal of Hematology and Transfusion Medicine (วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต) · doi:10.69898/jhtm.35.2025.275741 · Cited by 1
Self-citationGan, J., Huang, W., & Zhang, Y. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02073-0 · Cited by 1
Thalassemia syndromes and other hemoglobinopathies
Sheth, S. (2025) · doi:10.1182/ashsap9.chapter10 · Cited by 1
Levy, M., & Ginzburg, Y. Z. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_11 · Cited by 1
Luspatercept: known and unknown promises
Rivella, S. (2025) · Blood Red Cells & Iron · doi:10.1016/j.brci.2025.100009 · Cited by 1
Fujiwara, T., & Harigae, H. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2553648 · Cited by 1
Khamphikham, P., Tantiworawit, A., & Anuchapreeda, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333127 · Cited by 1
“Another strategy involves promoting erythroid survival and maturation, for example by inhibiting the SMAD2/3 pathway downstream of TGF-β signaling [10,11].”
Self-citationLi, X., Hong, W., Wu, J., Liu, Q., Liu, Y., Hu, S., Xu, L., Xu, H.-G., Zhong, D., Huang, J., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2561219 · Cited by 3
Regional Consistency Evaluation and Sample Size Calculation Under Two MRCTs
Qing, K., Ren, X., Jiang, S., Yang, P., Yu, M., & Xu, J. (2024) · Statistics in Medicine · doi:10.1002/sim.70306 · Cited by 3
“It is seen that (i) 𝑓 𝑘 depends not only on 𝑝 ( c ,𝑠 ) or 𝑑 ( 𝑠 ) , but also 𝑟 ( 𝑠 ) , under each combination of 𝛼 and 1 − 𝛽 𝑠 as expected and (ii) the calculated fraction of samples can yield the prespecified CP accurately with the average absolute error of 0.3% and 0.7% over all 18 and…”
InfluentialMultiomics analysis of red blood cells reveals thalassemia severity beyond globin gene mutations
Mitra, N., Bhattacharyya, U., Chowdhury, P. K., Pal, A., Korwar, A. M., Bhattacharjee, S., & Basu, A. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025016677 · Cited by 1
Ramnarayan, B., Setlur, K., Annegowda, V. M., Savita Mallikarjun, A., Pallavi Nanaiah, K., & Rangan, V. (2026) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2026.268821 · Cited by 1
“Historical benchmarks like the enhancement of HbF production by hydroxyurea [31] and clinical trials demonstrating the efficacy of luspatercept [32], crizanlizumab [33] , and HSCT [34] reinforce a growing therapeutic armamentarium for hemoglobinopathies.”
Gianesin, B., Zappu, A., Ferrero, G. B., Gaglioti, C. M., Santodirocco, M., Fania, G., Graziadei, G., Panzieri, D. L., Massa, A., Mina, T., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70437 · Cited by 1
“Despite the overall more severe clinical phenotype of this cohort, the effect of luspatercept on transfusion requirements remained statistically significant, with re-sults at least comparable to those reported in both the Italian real-world experience and/or the BELIEVE trial 1,2,7 (Figure 1).”
Self-citationSplenectomy in β‐thalassemia patients: Practices and risks in a nationwide study
Benoit, A., Pages, J., Szepetowski, S., Agouti, I., Thuret, I., Roux, É. L., Badens, C., Brousse, V. A. M., & Nathaly Network (2026) · HemaSphere · doi:10.1002/hem3.70350 · Cited by 1
Luspatercept in Transfusion‐Dependent Thalassemia With Red Blood Cell Antibodies: A Case Series
Teawtrakul, N. (2026) · eJHaem · doi:10.1002/jha2.70320 · Cited by 1
“Luspatercept is an erythroid maturation agent that improves late-stage erythropoiesis and reduces transfusion burden in adults with TDT [ 6, 7 ].”
Erythroferrone in β-thalassemia: Systematic review and meta-analysis
Saboor, M., & Abass, K. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121179 · Cited by 1
Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective
González‐Valdivieso, J., Gutiérrez, J., Calero, J. A. V., Escalera-Anzola, S., ̃oz, R. M., Arias, F. J., Rojo, M. A., & Girotti, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070831 · Cited by 1
“In the BELIEVE phase 3 trial, registered as NCT02604433 and EudraCT 2015-003224-31, Luspatercept reduced transfusion burden in transfusion-dependent β -thalassemia, and the least-squares mean difference in serum ferritin at week 48 favored luspatercept by 348 µ g/L [86].”
Implementation of thalassemia and hemoglobinopathy prevention and management programs in Thailand
Srichairatanakool, S., Charoenkwan, P., & Tantiworawit, A. (2026) · Blood Global Hematology · doi:10.1016/j.bglo.2026.100122 · Cited by 1
Self-citationRadhakrishnan, N., Dewan, P., Chandra, J., Sharma, R., Arora, S., Bhat, S., Kakkar, S., Jain, A., Prakash, A., Khanna, V. K., et al. (2026) · Indian Pediatrics · doi:10.1007/s13312-026-00366-9 · Cited by 2
Al-Samkari, H. T., Aboobacker, F., Andemariam, B., Eleftheriou, P., Ezzat, H. M., Farmakis, D. T., Hashmi, S. K., Kakkar, S., Maggio, A., Piga, A. G., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00197-3 · Cited by 2
Self-citationLuspatercept for Beta-thalassemia – A New Horizon?
Din, M. A. U., & Anwer, F. (2020) · European Oncology & Haematology · doi:10.17925/eoh.2020.16.1.16 · Cited by 1
Safety: A Primary Concern in Thalidomide Use in Thalassemia: Reply.
Chandra, J. (2021) · PubMed · Cited by 1
Targeting anemia in myeloid neoplasms
Gangat, N., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27408 · Cited by 2
Tefferi, A., & Gangat, N. (2025) · American Journal of Hematology · doi:10.1002/ajh.27638 · Cited by 1
The double edge of erythropoietic modulation in thalassaemia
Ricchi, P. (2025) · British Journal of Haematology · doi:10.1111/bjh.20142 · Cited by 1
“2,3 Its use has expanded significantly in recent years, and although its safety profile has remained largely favourable in pivotal clinical trial 4 and real-world settings, reports of previously undescribed adverse events, such as transient facial oedema, are emerging, 5 underscoring the need for…”
Generalidades y tratamientos emergentes en la Beta-talasemia
Ureña, G. J. A., Hernández, R. K., & Ortiz, J. M. M. (2020) · Revista Medica Sinergia · doi:10.31434/rms.v5i12.549 · Cited by 1
“El inicio de esta terapia previo a los 2 años de edad permite un crecimiento adecuado y evita la deformación ósea asociada a la expansión medular en la mayoría de pacientes (10).”
BackgroundInfluentialGeneralidades y tratamientos emergentes en la Beta-Talasemia
Ureña, G. J. A., Hernández, R. K., & Ortiz, J. M. M. (2021) · Revista Ciencia y Salud Integrando conocimientos · doi:10.34192/cienciaysalud.v5i1.219 · Cited by 1
Kopparthy, P., Kelkar, A. H., Aggarwal, K., Filippis, S. M. D., & Fletcher, B. (2021) · Cureus · doi:10.7759/cureus.13638 · Cited by 1
“Given the age, disease severity, and transfusion-dependence, our management likely would have changed to include luspatercept and potentially one of these gene therapies [13-14].”
BackgroundНарушения обмена железа и пути их фармакологической коррекции
Миронов, С. Е., Горбунов, А. А., Тихонов, Д. А., & Лемина, Е. Ю. (2022) · Экспериментальная и клиническая фармакология · doi:10.30906/0869-2092-2022-85-6-38-48 · Cited by 3
Approved Protein Therapeutics and Their Biochemical Targets
Ramesh, R., & Ravichandran, R. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_7 · Cited by 1
A deep dive into future therapies for microcytic anemias and clinical considerations
Rodrigues, F., Coman, T., Fouquet, G., Côté, F., Courtois, G., Maciel, T. T., & Hermine, O. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2206556 · Cited by 1
“In beta-thalassemia, they both reduce the transfusion burden and splenomegaly in humans while increasing hemoglobin [102,105,158].”
BackgroundSelf-citationLimwongse, C., Rojnuckarin, P., Kupatawintu, P., Thongthaisin, A., Permpikul, P., Kitpoka, P., Watanaboonyongcharoen, P., Sutcharitchan, P., Torcharus, K., Fucharoen, S., et al. (2023) · Transfusion Medicine · doi:10.1111/tme.13011 · Cited by 1
The Effect of Parental Support on the Quality of Life of Children with Thalassemia
Utami, W., Nazri, M., & Mokti, K. (2024) · South Eastern European Journal of Public Health · doi:10.70135/seejph.vi.672 · Cited by 1
“The Hematology Skills Competency Test results from the Indonesian Pediatrician Association in 2016 show that the prevalence of thalassaemia major in Indonesia was 9,121, according to the Ministry of Health of the Republic of Indonesia (2019) (1).”
BackgroundChandra, J. (2021) · Indian Pediatrics · doi:10.1007/s13312-021-2386-0 · Cited by 1
Haemoglobin and the inherited disorders of globin synthesis
Thein, S. L., & Rees, D. C. (2025) · Wiley eBooks · doi:10.1002/9781119706687.ch14 · Cited by 1
From Science to Solidarity: A Two‐Decade Collaboration in Thalassemia
Taher, A. T., & Cappellini, M. D. (2025) · American Journal of Hematology · doi:10.1002/ajh.70121 · Cited by 1
Self-citationDarvishi‐Khezri, H., & Karami, H. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01663-4
“In a recent clinical study [18]—as a doubleblind, controlled, phase-III trial—luspatercept was trialed on 336 b-thalassemia patients dependent on red cell transfusion to improve the transfusion requirements; 30.”
BackgroundInfluentialFreij, J. B. (2021) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1622160060
“, a randomized, double-blinded, phase 3 clinical trial comparing the efficacy of reducing transfusion requirements in β-thalassemia patients treated with luspatercept versus placebo.(10) This study recruited 336 patients with either β-thalassemia or hemoglobin-E (HgE) β-thalassemia who required transfusions of 6-20 pa…”
BackgroundWong, J. (2021) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380211048921
Völkl, A., & Oduncu, F. S. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23337-1.00004-7
Capellini, M. D., & Dooper, M. (2022) · doi:10.55788/ec912444
LUSPATERCEPT – A TREATMENT FOR THALASSEMIA?
Hassan, T. (2021) · Khyber Medical University Journal · doi:10.35845/kmuj.2021.21856
Almahmoud, R., Hussein, A., Alkhaja, F., Soliman, A. F., Dewedar, H., & Mathai, S. (2022) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_41_22
Diagnostik und Therapie der alpha- und beta-Thalassämien
Cario, H. (2023) · Transfusionsmedizin · doi:10.1055/a-1966-5765
Stem Cell Transplant for Hemoglobinopathies
Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-5802-1_28 · Cited by 2
Aziz, M. A. A. E., El-Sheikh, O. Y., Ahmed, G. E. N., & Attia, R. S. A. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns9.14529
Cario, H., & Lobitz, S. (2023) · Pädiatrie · doi:10.1007/s15014-023-5031-7
Conventional and Innovative Molecular Approaches Developed for Treating Hemoglobinopathies
Miliotou, Α. N., Georgiou‐Siafis, S. K., Vlachaki, E., Pappas, I. S., Vizirianakis, I. S., Tsiftsoglou, A. S., & Papadopoulou, L. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00025-1
Self-citationGDF11 level and its effect on prognosis in patients with acute myeloid leukemia
Aslan, N. A., Avcı, E., Şenol, H., & Güler, N. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241238218
Hämoglobinopathien und G6PDH-Mangel - global und lokal relevant*
Cario, H., & Lobitz, S. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0495-3
Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies
Farmakis, D. T., Angastiniotis, M., & Eleftheriou, A. (2024) · HemaSphere · doi:10.1002/hem3.114
Luspatercept for non‐deletional hemoglobin H disease
Yang, Y.-N., Chou, Y., & Cheng, C. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31224
Mitchell, H., Xin, Q., Hide, J., Halin, C., Tadwalkar, S. S., Hashim, S., & Hudson, R. D. A. (2024) · medRxiv · doi:10.1101/2024.08.06.24311489
“This analysis indicated that the technologies from the terminated NICE appraisals for multi-indication products assessed in this study could potentially reduce the need for rescue therapy, surgery, hospitalization, and transfusions (29, 33, 34, 38).”
BackgroundKhan, S. M., Sultana, N., Siddiqui, S., & Nizammuddin, M. (2024) · National Journal of Health Sciences · doi:10.21089/njhs.93.0149
Abuhelwa, Z., Cheng, J. H., & Li, J. Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-62373-8_12
Breaking the cycle of transfusion dependence in β-thalassaemia
Kuo, K. H. M., & Forté, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02514-5
Self-citationNonsurgical Approaches for Managing Hypersplenism in Thalassemia
Almohammadi, A. T. (2024) · Journal of Applied Hematology · doi:10.4103/joah.joah_94_24
Treatment options for anaemia in myelofibrosis
Gołoś, A., & Góra‐Tybor, J. (2024) · Acta Haematologica Polonica · doi:10.5603/ahp.102605
Khuzae, Z. H. A., Aseery, A. A., Asiri, H. A., Faqihi, N. H., Dawmari, M. A., & Alyami, N. B. S. (2025) · Cuestiones de Fisioterapia · doi:10.48047/tw5tza77
Domoń, D., Niedziela, A., Wilska, H., Domanowska, D., Liebert, A., Klimek, N., Kaplińska, M., Rutka, B., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3597
Luspatercept (REBLOZYL): A Game-Changer in Reducing Transfusion Burden for β-Thalassemia Patients
Advani, A., & Mughal, S. A. (2025) · Innovative Research in Applied Biological and Chemical Sciences · doi:10.62497/irabcs.150
Benítez‐Carabante, M. I., Lopez, A. M., Oficialdegui, M. L. U., Beléndez, C., Romero, M. P., Plaza, M., Fuentes, C., Enríquez, S. V., Silva, G. G., López‐Duarte, M., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.09.012
Insights Into Hemoglobinopathies in Spain: A Comprehensive Review
Corrons, J. V. (2025) · eJHaem · doi:10.1002/jha2.70093
“Clinical trials have shown that luspatercept significantly reduces transfusion requirements and improves hemoglobin levels in adult patients with TDT, representing a paradigm shift in management [28, 29].”
Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion BurdenPreprint
Wang, L., Jin, S., Pan, M., Gao, W., Pan, Z., Mi, J., Zhang, W., & Hu, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7900872/v1
Medical management of thalassaemia: Pushing boundaries with limited resources
Mettananda, S. (2025) · Sri Lanka Journal of Child Health · doi:10.4038/sljch.v54i4.11585
Metadata
- Authors
- Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L.-P., Bee, P.-C., Lim, S.-M., Lu, M.-Y., Tantiworawit, A., Ganeva, P., Gercheva, L., Shah, F., Neufeld, E. J., Thompson, A., Laadem, A., Shetty, J. K., Zou, J., Zhang, J., Miteva, D., Zinger, T., Linde, P. G., Sherman, M. L., Hermine, O., Porter, J., & Piga, A.
- Affiliations
- University of Milan (IT)
- Siriraj Hospital (TH)
- University Health Network (CA)
- University of Southern California (US)
- From the Department of Clinical Sciences and Community, University of Milan, IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, Milan (M.D.C.), Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, E.O. Ospedali Galliera, Genoa (G.L.F.), Ospedale Pediatrico Microcitemico A. Cao, Azienda Ospedaliera G. Brotzu, Cagliari (R.O.), Ematologia e Oncologia Pediatrica, Università della Campania L. Vanvitelli, Caserta (S.P.), and the Department of Clinical and Biological...
- University of California, San Francisco (US)
- The University of Sydney (AU)
- University Malaya Medical Centre (MY)
- St. Jude Children's Research Hospital (US)
- Lurie Children's Hospital (US)
- Hôpital Necker-Enfants Malades (FR)
- University College London Hospitals NHS Foundation Trust (GB)
- ORCID
- Cappellini, M. Domenica
- Viprakasit, Vip
- Taher, Ali T.
- Georgiev, Pencho
- Kuo, Kevin H.M.
- Coates, Thomas
- Voskaridou, Ersi
- Perrotta, Silverio
- Lal, Ashutosh
- Kattamis, Antonis
- Vlachaki, Efthymia
- Origa, Raffaella
- Ho, P. Joy
- Bee, Ping-Chong
- Lu, Meng-Yao
- Tantiworawit, Adisak
- Gercheva, Liana
- Shah, Farrukh
- Neufeld, Ellis J.
- Thompson, Alexis
- Laadem, Abderrahmane
- Shetty, Jeevan K.
- Sherman, Matthew L.
- Hermine, Olivier
- Piga, Antonio
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-26
- Volume
- 382
- Issue
- 13
- Pages
- 1219-1231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3014005795
- Cited by
- 332
- References
- 28
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 57 · 2023: 49 · 2022: 54 · 2021: 52 · 2020: 21
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Acceleron Pharma
- Celgene
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- transfusion-dependent beta-thalassemia, transfusion burden, erythroid maturation, recombinant fusion protein, serum ferritin, iron overload, adverse events, hyperuricemia, hypertension, bone pain, joint pain, dizziness, best supportive care
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Ferritins, Hematinics, Humans, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Splenectomy, Odds Ratio, Least-Squares Analysis, beta-Thalassemia, Erythrocyte Transfusion, Activin Receptors, Type II, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.